Nicholas Donoghoe Biography and Net Worth

SVP of AbbVie

As Senior Vice President, R&D Chief Operating Officer Nicholas Donoghoe oversees the operational and strategic execution of our pipeline across the R&D organization. In addition, Dr. Donoghoe leads the portfolio wide capability building that increase AbbVie’s agility, speed and cross-functional execution to unlock the full potential of our portfolio.

Dr. Donoghoe joined AbbVie in 2019 in a newly created Innovation role to support corporate growth through cross-functional efforts across the company.  In 2020, he then led Global Strategy and Operations for Allergan Aesthetics with responsibility for pipeline marketing, customer service, analytics, and commercial strategy.

In 2021, Nicholas was asked to lead Portfolio Innovation across both the Aesthetics and Therapeutics businesses to define and implement transformational initiatives that directly impact short- and long-term goals and the future success of AbbVie.

Dr. Donoghoe views his work through a unique lens of business and scientific acumen, having served as a partner at McKinsey and holding an M.D. from Johns Hopkins University and a B.S. from Duke University. During his time at McKinsey, he served global clients across a broad range of geographies and therapeutic areas, including oncology, immunology, and neuroscience. 

What is Nicholas Donoghoe's net worth?

The estimated net worth of Nicholas Donoghoe is at least $8.66 million as of March 20th, 2024. Dr. Donoghoe owns 55,903 shares of AbbVie stock worth more than $8,657,139 as of May 29th. This net worth approximation does not reflect any other assets that Dr. Donoghoe may own. Learn More about Nicholas Donoghoe's net worth.

How do I contact Nicholas Donoghoe?

The corporate mailing address for Dr. Donoghoe and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Nicholas Donoghoe's contact information.

Has Nicholas Donoghoe been buying or selling shares of AbbVie?

Nicholas Donoghoe has not been actively trading shares of AbbVie over the course of the past ninety days. Most recently, Nicholas Donoghoe sold 21,082 shares of the business's stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $176.30, for a transaction totalling $3,716,756.60. Following the completion of the sale, the executive vice president now directly owns 55,903 shares of the company's stock, valued at $9,855,698.90. Learn More on Nicholas Donoghoe's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 11 times. They sold a total of 404,736 shares worth more than $70,989,822.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 3/20/2024.

Nicholas Donoghoe Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/20/2024Sell21,082$176.30$3,716,756.6055,903View SEC Filing Icon  
12/26/2023Sell2,912$154.72$450,544.6455,903View SEC Filing Icon  
8/29/2019Buy7,525$66.19$498,079.7513,090View SEC Filing Icon  
See Full Table

Nicholas Donoghoe Buying and Selling Activity at AbbVie

This chart shows Nicholas Donoghoe's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $154.86
Low: $153.68
High: $156.38

50 Day Range

MA: $166.60
Low: $154.86
High: $182.10

2 Week Range

Now: $154.86
Low: $130.96
High: $182.89


4,253,188 shs

Average Volume

5,499,255 shs

Market Capitalization

$273.46 billion

P/E Ratio


Dividend Yield